Search Results 161-170 of 3415 for 搜索痕迹咨询邮箱:lgooxc@hotmail.com
About this study. This study aims to demonstrate that the efficacy of treatment with selumetinib as measured by event-free survival (EFS) is non-inferior ...
This study aims to facilitate discovery and validation of tests for early detection in subjects at high risk for pancreatic ductal adenocarcinoma (PDAC). and to ...
Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and ...
Laurence J. Miller, M.D. · Mayo Clinic Collaborative Research Building 3A 13400 E. Shea Blvd. Scottsdale, AZ 85259 · Tel: 480-301-4217 · Fax: 480-301-8387 · Email: ...
Bernard R. Bendok, M.D. · Principal Investigator · Neurosurgery Simulation and Innovations Laboratory · Mayo Clinic 5777 E. Mayo Blvd. Phoenix, AZ 85054 · Email: ...
The purpose of this study is to investigate the impact of concurrent LiSWT on patient-reported outcomes including symptom bother using the validated Peyronie's ...
William A. Faubion Jr., M.D. · Immuno-Epigenetics Laboratory · Mayo Clinic 200 First St. SW Rochester, MN 55905 · Phone: 507-293-0970 · Email: faubion.william@mayo.
You also can request a consultation. American Joint Replacement Research-Collaborative (AJRR-C); Mayo Clinic 200 First St. SW Rochester, MN 55905; Email: ...
For information about making a gift, call 855-852-8129. To request a medical appointment, see Appointments at Mayo Clinic. Email. development@mayo.edu. Mail.
Ibrutinib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Rituximab is a monoclonal antibody that may interfere with ...
Mayo Clinic does not endorse companies or products. Advertising revenue supports our not-for-profit mission.
Check out these best-sellers and special offers on books and newsletters from Mayo Clinic Press.
The deadline to have twice the impact to advance healthcare research is May 15.